QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
NASDAQ:SAVA

Cassava Sciences (SAVA) Stock Price, News & Analysis

$22.51
-0.49 (-2.13%)
(As of 03/4/2024 ET)
Today's Range
$22.21
$23.19
50-Day Range
$21.92
$26.41
52-Week Range
$12.32
$32.10
Volume
632,375 shs
Average Volume
661,551 shs
Market Capitalization
$972.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$88.57

Cassava Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
293.5% Upside
$88.57 Price Target
Short Interest
Bearish
30.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
-0.03mentions of Cassava Sciences in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.41 out of 5 stars

Medical Sector

377th out of 948 stocks

Pharmaceutical Preparations Industry

178th out of 436 stocks


SAVA stock logo

About Cassava Sciences Stock (NASDAQ:SAVA)

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

SAVA Stock Price History

SAVA Stock News Headlines

3 small-cap biotechs with potential breakthroughs in 2024 (SAVA)
These small-cap biotech stocks feature large addressable markets combined with positive analyst sentiment and potential breakthroughs in 2024.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Cassava Deadline Reminder
SAVA Apr 2024 21.000 put
SAVA Mar 2024 19.500 call
SAVA Aug 2024 15.000 put
SAVA Mar 2024 24.000 put
Cassava Sciences Investor Deadline Approaching
Exit Now! 3 Biotech Stocks to Sell in February 2024
SAVA Feb 2024 32.000 call
SAVA Feb 2024 18.500 put
Cassava Sciences Inc (SAVA)
See More Headlines
Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/01/2023
Today
3/04/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SAVA
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$88.57
High Stock Price Target
$88.57
Low Stock Price Target
$88.57
Potential Upside/Downside
+292.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-97,220,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.26 per share

Miscellaneous

Free Float
38,859,000
Market Cap
$975.91 million
Optionable
Optionable
Beta
-0.42
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Remi Barbier (Age 64)
    Founder, Chairman, President & CEO
    Comp: $1.11M
  • Mr. Eric J. Schoen (Age 56)
    Chief Financial Officer
    Comp: $426.61k
  • Mr. R. Christopher Cook (Age 60)
    Senior VP, Company Secretary & General Counsel
    Comp: $457.64k
  • Dr. James W. Kupiec M.D. (Age 71)
    Chief Medical Officer
    Comp: $400k
  • Dr. George Thornton
    Senior Vice President of Technology
  • Mr. Michael Zamloot
    Senior Vice President of Technical Operations
  • Dr. Michael Marsman Pharm.D.
    Senior Vice President of Regulatory Affairs
  • Dr. Lindsay H. Burns Ph.D.
    Senior Vice President of Neuroscience














SAVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Cassava Sciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SAVA shares.
View SAVA analyst ratings
or view top-rated stocks.

What is Cassava Sciences' stock price target for 2024?

1 brokerages have issued 1 year price objectives for Cassava Sciences' stock. Their SAVA share price targets range from $88.57 to $88.57. On average, they expect the company's share price to reach $88.57 in the next twelve months. This suggests a possible upside of 293.5% from the stock's current price.
View analysts price targets for SAVA
or view top-rated stocks among Wall Street analysts.

How have SAVA shares performed in 2024?

Cassava Sciences' stock was trading at $22.51 at the start of the year. Since then, SAVA stock has increased by 0.0% and is now trading at $22.51.
View the best growth stocks for 2024 here
.

When is Cassava Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our SAVA earnings forecast
.

How were Cassava Sciences' earnings last quarter?

Cassava Sciences, Inc. (NASDAQ:SAVA) posted its earnings results on Monday, May, 1st. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.01.

What ETFs hold Cassava Sciences' stock?
When did Cassava Sciences' stock split?

Cassava Sciences's stock split on the morning of Thursday, December 21st 2023. The 14-10 split was announced on Thursday, December 21st 2023. The newly minted shares were issued to shareholders after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split.

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.51%), Gallacher Capital Management LLC (1.38%), Northern Trust Corp (0.92%), Charles Schwab Investment Management Inc. (0.73%), Nuveen Asset Management LLC (0.66%) and Norges Bank (0.51%). Insiders that own company stock include Eric Schoen, James William Kupiec, Richard Barry and Sanford Robertson.
View institutional ownership trends
.

How do I buy shares of Cassava Sciences?

Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SAVA) was last updated on 3/4/2024 by MarketBeat.com Staff